期刊文献+

睾酮凝胶体外透皮吸收的特征 被引量:1

In vitro transdermal absorption peculiarity of testosterone gel
原文传递
导出
摘要 目的建立睾酮凝胶剂体外透皮吸收试验方法并考察其体外经皮吸收特性。方法采用单室扩散池,大鼠皮肤作为试验材料,以乙醇-生理盐水(3:7,V/V)为接收液,恒温32℃,分别于设定时间取样,用HPLC法测定接受液中睾酮含量。结果累积渗透量Q(μg·cm^(-2)对t(h)进行线性回归,方程为Q=108.706 9 t+65.4318,r=0.996 8,求算透皮速率常数J为108.7μg·cm^(-2)·h^(-1)。结论所建立的体外透皮吸收模型和方法可以较好评价睾酮凝胶剂的体外透皮吸收特性。 A/M To establish a method for transdennal absorption experiments in vitro of testosterone gel and evaluate its skin permeation in-vitro. METHODS The in-vitro skin permeation of the testosterone gel was characterized on rat skin by using Franz diffusion cell. The receiving solution was ethanol-normal saline (3:7, V/V),and the temperature was maintained at 32℃. Samples were withdrawn from the receiving solution at certain time intervals, and the concentration of testosterone was measured by HPLC. RESULTS The linear regressive analysis for the cumulative permeation quantity (Q) and the time (t) was carried out.The equation was Q = 108. 706 9t + 65.431 8, r = 0.996 8.The transdermal speed constant(J) of the gel was 108.7 μg·cm^-2· h ^-1. CONCLUSION The established in vitro transdermal test can be used to evaluate the permeation behavior of testosterone gel.
出处 《中国临床药学杂志》 CAS 2009年第6期353-355,共3页 Chinese Journal of Clinical Pharmacy
关键词 透皮吸收 睾酮 凝胶 高效液相色谱 transdermal absorption testosterone gel HPLC
  • 相关文献

参考文献3

  • 1崔毓桂,贾悦,狄福松,王兴海.男性性腺功能低减的雄激素替代治疗[J].中华男科学杂志,2003,9(3):210-213. 被引量:3
  • 2Dudley RE, Kottayil SG, Palatchi O. Pharmaceutical composition and method for treating hypogonadism: US, 6503894 [ P/OL]. 2003-01-7 [ 2009-04-20]. http://www, patentstorm, us/patents/6503894, html.
  • 3韩可勤.医药应用数理统计[M].南京:东南大学出版社,2009:105.

二级参考文献15

  • 1Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism[J]. Mol Cell Endocrinol, 2000, 161(1-2) :73-88.
  • 2Parker S, Armitage M. Experience with transdermal testosterone replacement therapy for hypogonadal men [ J ]. Clin Endocrinol( Oxf), 1999, 50( 1 ) :57-62.
  • 3Fossa SD, Opjordsmoen S, Haug E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer[ J].Eur J Cancer, 1999, 35(8): 1220-1225.
  • 4Curran MJ, Bihrle W 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate [ J ]. Urology, 1999, 53 ( 2 ) :423-424.
  • 5Anderson RA, Martin CW, Kung AW,et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men [ J ]. J Clin Endocrinol Metab, 1999, 84 (10) : 3556-3562.
  • 6Kelleher S, Turner L, Howe C, et al. Extrusion of testosterone pellets:a randomized controlled clinical study [ J]. Clin Endocrinol (Oxf) , 1999, 51 (4) :469-471.
  • 7Hellstrom WJC. The handbook of sexual dysfunction [ M ]. San Francisco: The American Society of Andrology, 1999.18-26, 39-42.
  • 8Yen SSC, Jaffe RB, Barbieri RL. Reproductive endocrinology:physiology, pathophysiology, and clinical management [ M ]. 4th Ed. England: Harcourt Publishers Limited, 1999. 622-668.
  • 9Kaiser FE. Erectile dysfunction in the aging man [J]. Med Clin North Am, 1999, 83(5):1267-1278.
  • 10Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men[J]. Drugs Aging, 1999, 15(2) :131-142.

共引文献3

同被引文献3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部